摘要
肝细胞癌是全世界范围内常见的高致死性恶性肿瘤之一,如何有效实现其早期诊断、治疗效果监测以及预后评估具有重要临床意义。循环肿瘤DNA(ctDNA)作为一种新型液体活检标志物,在肝细胞癌的诊断与治疗中展现出显著的应用潜力。笔者系统介绍ctDNA在肝细胞癌早期诊断、治疗监测和预后评估方面的最新研究进展,深入阐述其在精准医疗中的独特优势及临床应用价值。
Hepatocellular carcinoma(HCC)remains a leading cause of cancer-related death worldwide,emphasizing the utmost importance of early diagnosis,therapeutic monitoring,and pro-gnostic assessment.Circulating tumor DNA(ctDNA),as an innovative liquid biopsy biomarker,has demonstrated unique advantages in HCC management.The authors systematically summarized recent advances in the application of ctDNA for early diagnosis,therapeutic monitoring,and prognostic evaluation of HCC,focusing on its advantages and clinical application value in precision medicine.
作者
赫明达
杨钰泽
王明达
李超
吴寒
杨田
He Mingda;Yang Yuze;Wang Mingda;Li Chao;Wu Han;Yang Tian(Basic Medical College,Naval Medical University,Shanghai 200433,China;The First Ward of Hepato-biliary and Pancreatic Surgery,Department of General Surgery,First Hospital of Jilin University,Changchun 130031,China;Department of Hepatic Surgery,Third Affiliated Hospital of Naval Medical University(Shanghai Eastern Hepatobiliary Surgery Hospital),Shanghai 200438,China)
出处
《中华消化外科杂志》
北大核心
2025年第1期86-92,共7页
Chinese Journal of Digestive Surgery
基金
国家自然科学基金(82425049,82273074,81972726)
上海市优秀学术带头人计划项目(23XD1424900)
上海市卫生健康学科带头人项目(2022XD001)
上海市自然科学基金(22ZR1477900)。
关键词
肝肿瘤
循环肿瘤DNA
诊断
治疗监测
预后评估
Liver neoplasms
Circulating tumor DNA
Diagnosis
Therapeutic monitor-ing
Prognostic assessment
